NextGen enters accord with Harvard Institute of Proteomics

3 December 2007

NextGen Sciences, a UK-based provider of gene-to-protein products and services, has commenced its collaboration with the Harvard Institute of Proteomics, which will focus on integrating the company's information management software, orchestratorIMS, with Harvard's extensive clone database in order to develop advanced automated methods for multi-construct design.

As part of the program, the institutions will work in partnership with NextGen to inform the co-development of new product and technology enhancements. By combining their leading data management systems, researchers will be able to design research projects and implement them using NextGen's leading automated expressionworkstation platform, the firm noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight